NEUROLOGICAL RISKS AND BENEFITS OF CYTOKINE-BASED TREATMENTS IN COVID-19: A JOURNEY FROM PRECLINICAL TO CLINICAL EVIDENCE

GIUSEPPE PIGNATARO¹, Mauro Cataldi¹, and Maurizio Taglialatela¹

¹Università degli Studi di Napoli Federico II


November 5, 2020

Abstract

IImmunodeficiency and hyperinflammation characterize COVID-19 associated states; thus, repurposing of multiple cytokine and/or anti-cytokine drugs currently being used in other therapeutic areas has been suggested as a potential therapeutic strategy in COVID-19 patients. Clinical trials involving these drugs target the most frequent and life-threatening peripheral consequences of the disease, mainly focusing on lung, heart, and coagulation functions; however, a growing number of reports describe a wide range of COVID-associated neurological manifestations (altogether defined as neuro-COVID) including anosmia, seizures, confusion, stroke, encephalopathy, and paralysis. Notably, the underlying pathophysiological mechanisms for neuro-COVID may also include dysregulation of cytokines/chemokines, deficiencies in the innate immune response, and autoimmunity. This suggests that therapeutic attempts with drugs targeting cytokine-mediated inflammation in peripheral organs could also positively affect neuro-COVID manifestations. As a matter of fact, some of these drugs have also been scrutinized for their potential efficacy in treating neuroinflammatory diseases such as optic neuromyelitis, epilepsy, stroke, and traumatic brain injury, among others. On the other hand, anti-cytokine drugs, by impairing relevant physiological activities exerted by these mediators in the CNS, may also be endowed with significant neurological risk. Therefore, the primary aim of the present manuscript is to review the available preclinical and clinical data regarding the neurological effects of the drugs targeting cytokine-mediated inflammation, in order to raise awareness about their potentially beneficial or detrimental neurological consequences when used to treat COVID-19 patients.

Hosted file

COVID and Cytokine-based therapies 4_11_2020.pdf available at https://authorea.com/users/ 344230/articles/491015-neurological-risks-and-benefits-of-cytokine-based-treatments-incovid-19-a-journey-from-preclinical-to-clinical-evidence



Hosted file

Table BJP 04-11-2020_TABLE1.pdf available at https://authorea.com/users/344230/articles/ 491015-neurological-risks-and-benefits-of-cytokine-based-treatments-in-covid-19-ajourney-from-preclinical-to-clinical-evidence

Hosted file

Table BJP 04-11-2020_TABLE2.pdf available at https://authorea.com/users/344230/articles/ 491015-neurological-risks-and-benefits-of-cytokine-based-treatments-in-covid-19-ajourney-from-preclinical-to-clinical-evidence

	Table 3. NEUROINFLAMMATION AND CYTOKINE-TARGETED INTERVENTIONS : Targeting TNF- $lpha$					
Target	Drug	Main Indications	CT Number , Title, Study Protocol	Neurological Implications		
TNF-α	Infliximab Anti-TNF-a antibody	•Rheumatoid Arthritis •Psoriatic Arthritis •Plaque Psoriasis •Crohn Disease •Ulcerative Colitis •Ankylosing Spondylitis •Idiopathic Pulmonary Fibrosis (Orphan)	NCT0425338 A Phase 2 Trail of Influximab in Coronavirus Disease 2019 (COVID-19). Interventional Phase 2	Not approved for any neurological condition. May cause a variety of neuroimmune adverse events, such as optic neuritis, chronic inflammatory demyelinating polyneuropathy, mononeuritis multiplex, Guillain-Barté syndrome (Kemanetzogiou et al., 2017), vasculitis and amyloidosi; (Theibich et al., 2014), and serious encephalitis, mainly of herpetic etiology (Bradford et al., 2009). May cause herpes zoster reactivation (Strangfeld et al.,2009).		
	Adalimumab Anti-TNF-α antibody	•Rheumatoid Arthritis •Juvenile Idiopathic Arthritis •Psoriatic Arthritis •Plaque Psoriasis •Crohn's Disease •Ulcerative Colitis •Ankylosing Spondylitis •Hidradenitis Suppurativa •Uveitis	ClaCTE200030089 A randomized, poer-label, controlled trial for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19) Interventional Phase 2	Athough not approved for any neurological condition, it has been successfully used in Rasmussen encephallis (Lagarde et al., 2016). However, demyelinating disorders, herpes zoster reactivation and herpes zoster meningitis have been associated with its use (Bradford et al., 2009; Ma et al., 2013; Strangfeld et al., 2009; Zhu et al., 2016).		

Table 4. NEUROINFLAMMATION AND CYTOKINE-TARGETED INTERVENTIONS : Targeting IFN-Y					
Target	Drug	Main Indications	CT Number , Title, Study Protocol	Neurological Implications	
IFN-γ	Emapalumab Anti-IFN-γ antibody	•Primary Hemophagocytic Lymphohistiocytosis (HLH)	NCT04324021 Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients WHL COVID-19 Infection. Interventional Phase 2/3	In patients affected by Adenosine Deaminase Deficiency- Severe Combined Immunodeficiency (ADA-SCID), emapalumab reduced the size of brain lesions caused by CNS Tubercolosis infection (Tucci et al., 2020).	

Hosted file

Table BJP 04-11-2020_TABLE5.pdf available at https://authorea.com/users/344230/articles/ 491015-neurological-risks-and-benefits-of-cytokine-based-treatments-in-covid-19-ajourney-from-preclinical-to-clinical-evidence

Hosted file

Table BJP 04-11-2020_TABLE6.pdf available at https://authorea.com/users/344230/articles/ 491015-neurological-risks-and-benefits-of-cytokine-based-treatments-in-covid-19-ajourney-from-preclinical-to-clinical-evidence

	Table 7. NEUROINFLAMMATION AND CYTOKINE-TARGETED INTERVENTIONS : Targeting IL-7					
Target	Drug	Main Indications	CT Number , Title, Study Protocol	Neurological Implications		
IL-7	CYT-107 Recombinant Interleukin-7		NCT04379076 InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort (ILIAD-7-UK) Interventional Phase 2	IL-7 is effective in patients with progressive multifocal leukoencephalopathy caused by JC polyomavirus (Alstadhaug et al., 2014). May also exert proinflammatory activity (Ziegler et al., 1991) during spinal trauma (Bao et al., 2018)		
			NCT04407689 InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort (ILIAD-7-FR) Interventional Phase 2	and promote the autoimmune aggression of the CNS in EAE mice (Lawson et al., 2015,Walline et al., 2011).		
			NCT04426201 InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (ILIAD-7-US-0) (ILIAD-7-US-0) Interventional Phase 2			
			NCT04442178 InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (ILIAD-7-U-5-1) (ILIAD-7-U5-1) Interventional Phase 2			

Table 8. NEUROINFLAMMATION AND CYTOKINE-TARGETED INTERVENTIONS : Targeting Complement System					
Target	Drug	Main Indications	CT Number , Title, Study Protocol	Neurological Implications	
Complement System	Eculizumab Anti-C5 antibody	Paroxysmal nocturnal hemoglobinuria Atypical hemolytic	NCT04346797 CORIMUN019-ECU: Trial Evaluating Efficacy and Safety of Eculizamab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUN0-19 Cohort (CORIMUN019-ECU) Interventional Phase 2	Approved for neuromyelitis optica (Carparini et al., 2019), and myasthenia gravis (Frampton, 2020). Effective in patients with a genetic demyelinating neuropathy caused by CDS9 mutation (Mevorach	
		uremic syndrome •Generalized myasthenia gravis •Neuromyelitis optica spectrum disorder	NCT04355494 SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 Expanded Access	et al., 2016). It may aggravate progressive multifoca leukoencephalopathy caused by JC polyomaviru (Gomez-Cibeira et al., 2016).	
			NCT04288713 Eculizumab (Soliris) in Covid-19 Infected Patients (SOLID-C19) Expanded Access		